Impax Investors Get New Go at Some Drug Price-Fixing Allegations

Impax Laboratories Inc. investors will get another chance to hold the company liable for allegedly misleading them about generic drug price-fixing after the Ninth Circuit partially reversed the lower court’s dismissal in an unpublished opinion Monday.

The pharmaceutical firm’s investors properly alleged that Impax made misleading statements and caused some of their losses, the U.S. Court of Appeals for the Ninth Circuit said. But the district judge was right to dismiss some parts of the would-be class complaint, according to the opinion.

The investors properly alleged that Impax “agreed with co-conspirators to fix prices of generic drugs and strategically ...